Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.
<h4>Background</h4>Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan Africa. In recent years, serogroup W135 has also been the cause of epidemics. Mass vaccination campaigns with polysaccharide vaccines are key elements in controllin...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-01-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0000342&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172205280788480 |
|---|---|
| author | Philippe J Guerin Lisbeth M Naess Carole Fogg Einar Rosenqvist Loretxu Pinoges Francis Bajunirwe Carolyn Nabasumba Ray Borrow Leif O Frøholm Salah Ghabri Vincent Batwala Rogers Twesigye Ingeborg S Aaberge John-Arne Røttingen Patrice Piola Dominique A Caugant |
| author_facet | Philippe J Guerin Lisbeth M Naess Carole Fogg Einar Rosenqvist Loretxu Pinoges Francis Bajunirwe Carolyn Nabasumba Ray Borrow Leif O Frøholm Salah Ghabri Vincent Batwala Rogers Twesigye Ingeborg S Aaberge John-Arne Røttingen Patrice Piola Dominique A Caugant |
| author_sort | Philippe J Guerin |
| collection | DOAJ |
| description | <h4>Background</h4>Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan Africa. In recent years, serogroup W135 has also been the cause of epidemics. Mass vaccination campaigns with polysaccharide vaccines are key elements in controlling these epidemics. Facing global vaccine shortage, we explored the use of fractional doses of a licensed A/C/Y/W135 polysaccharide meningococcal vaccine.<h4>Methods and findings</h4>We conducted a randomized, non-inferiority trial in 750 healthy volunteers 2-19 years old in Mbarara, Uganda, to compare the immune response of the full dose of the vaccine versus fractional doses (1/5 or 1/10). Safety and tolerability data were collected for all subjects during the 4 weeks following the injection. Pre- and post-vaccination sera were analyzed by measuring serum bactericidal activity (SBA) with baby rabbit complement. A responder was defined as a subject with a > or =4-fold increase in SBA against a target strain from each serogroup and SBA titer > or =128. For serogroup W135, 94% and 97% of the vaccinees in the 1/5- and 1/10-dose arms, respectively, were responders, versus 94% in the full-dose arm; for serogroup A, 92% and 88% were responders, respectively, versus 95%. Non-inferiority was demonstrated between the full dose and both fractional doses in SBA seroresponse against serogroups W135 and Y, in total population analysis. Non-inferiority was shown between the full and 1/5 doses for serogroup A in the population non-immune prior to vaccination. Non-inferiority was not shown for any of the fractionate doses for serogroup C. Safety and tolerability data were favourable, as observed in other studies.<h4>Conclusions</h4>While the advent of conjugate A vaccine is anticipated to largely contribute to control serogroup A outbreaks in Africa, the scale-up of its production will not cover the entire "Meningitis Belt" target population for at least the next 3 to 5 years. In view of the current shortage of meningococcal vaccines for Africa, the use of 1/5 fractional doses should be considered as an alternative in mass vaccination campaigns.<h4>Trial registration</h4>ClinicalTrials.gov NCT00271479. |
| format | Article |
| id | doaj-art-0fa0f81898a442ac9570fce2e9b11dff |
| institution | OA Journals |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-0fa0f81898a442ac9570fce2e9b11dff2025-08-20T02:20:09ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352008-01-01212e34210.1371/journal.pntd.0000342Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.Philippe J GuerinLisbeth M NaessCarole FoggEinar RosenqvistLoretxu PinogesFrancis BajunirweCarolyn NabasumbaRay BorrowLeif O FrøholmSalah GhabriVincent BatwalaRogers TwesigyeIngeborg S AabergeJohn-Arne RøttingenPatrice PiolaDominique A Caugant<h4>Background</h4>Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan Africa. In recent years, serogroup W135 has also been the cause of epidemics. Mass vaccination campaigns with polysaccharide vaccines are key elements in controlling these epidemics. Facing global vaccine shortage, we explored the use of fractional doses of a licensed A/C/Y/W135 polysaccharide meningococcal vaccine.<h4>Methods and findings</h4>We conducted a randomized, non-inferiority trial in 750 healthy volunteers 2-19 years old in Mbarara, Uganda, to compare the immune response of the full dose of the vaccine versus fractional doses (1/5 or 1/10). Safety and tolerability data were collected for all subjects during the 4 weeks following the injection. Pre- and post-vaccination sera were analyzed by measuring serum bactericidal activity (SBA) with baby rabbit complement. A responder was defined as a subject with a > or =4-fold increase in SBA against a target strain from each serogroup and SBA titer > or =128. For serogroup W135, 94% and 97% of the vaccinees in the 1/5- and 1/10-dose arms, respectively, were responders, versus 94% in the full-dose arm; for serogroup A, 92% and 88% were responders, respectively, versus 95%. Non-inferiority was demonstrated between the full dose and both fractional doses in SBA seroresponse against serogroups W135 and Y, in total population analysis. Non-inferiority was shown between the full and 1/5 doses for serogroup A in the population non-immune prior to vaccination. Non-inferiority was not shown for any of the fractionate doses for serogroup C. Safety and tolerability data were favourable, as observed in other studies.<h4>Conclusions</h4>While the advent of conjugate A vaccine is anticipated to largely contribute to control serogroup A outbreaks in Africa, the scale-up of its production will not cover the entire "Meningitis Belt" target population for at least the next 3 to 5 years. In view of the current shortage of meningococcal vaccines for Africa, the use of 1/5 fractional doses should be considered as an alternative in mass vaccination campaigns.<h4>Trial registration</h4>ClinicalTrials.gov NCT00271479.https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0000342&type=printable |
| spellingShingle | Philippe J Guerin Lisbeth M Naess Carole Fogg Einar Rosenqvist Loretxu Pinoges Francis Bajunirwe Carolyn Nabasumba Ray Borrow Leif O Frøholm Salah Ghabri Vincent Batwala Rogers Twesigye Ingeborg S Aaberge John-Arne Røttingen Patrice Piola Dominique A Caugant Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLoS Neglected Tropical Diseases |
| title | Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. |
| title_full | Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. |
| title_fullStr | Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. |
| title_full_unstemmed | Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. |
| title_short | Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. |
| title_sort | immunogenicity of fractional doses of tetravalent a c y w135 meningococcal polysaccharide vaccine results from a randomized non inferiority controlled trial in uganda |
| url | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0000342&type=printable |
| work_keys_str_mv | AT philippejguerin immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT lisbethmnaess immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT carolefogg immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT einarrosenqvist immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT loretxupinoges immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT francisbajunirwe immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT carolynnabasumba immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT rayborrow immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT leifofrøholm immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT salahghabri immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT vincentbatwala immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT rogerstwesigye immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT ingeborgsaaberge immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT johnarnerøttingen immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT patricepiola immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda AT dominiqueacaugant immunogenicityoffractionaldosesoftetravalentacyw135meningococcalpolysaccharidevaccineresultsfromarandomizednoninferioritycontrolledtrialinuganda |